Skip to main content
SpringerLink
Log in

Cystic Fibrosis: Carrier Testing, Newborn Screening, and Diagnostic Testing

  • Chapter
  • First Online:
Molecular Diagnostics

Part of the book series: Molecular and Translational Medicine ((MOLEMED))

  • 2215 Accesses

Abstract

Cystic fibrosis (CF) is the most common life-shortening autosomal recessive genetic disorder in the Caucasian population. CF is due to mutations in the cystic fibrosis transmembrane regulator (CFTR) gene, located on chromosome 7 at 7q31.2, which encodes a cyclic AMP-activated chloride channel [1, 2]. The disorder has a broad range of severity, but classical CF is manifested by chronic pulmonary disease, exocrine pancreatic insufficiency, and elevated concentrations of chloride in sweat. Approximately 85 % of individuals with CF do not retain sufficient exocrine pancreatic function to adequately digest food. Thus, without oral pancreatic enzyme supplementation, severe malnutrition and growth failure can occur within the first years of life. The major cause of morbidity and mortality in CF is the chronic, suppurative pulmonary disease. The CF lung is extremely susceptible to infection, particularly with the mucoid form of the gram negative bacterium Pseudomonas aeruginosa and the gram-positive Staphylococcus aureus [3]. Although the details are still unclear, the mechanism of the lung disease is thought to originate in the relative lack of airway surface hydration due to abnormal sodium and chloride transport and the associated movement of water across the apical epithelia. The dehydrated mucus lining the airways becomes difficult for the cilia to move and clear trapped particulate matter, including inhaled bacteria. Subsequent bacterial growth stimulates inflammation and mucus hypersecretion, which in turn becomes dehydrated and difficult to expel. Thus, there is cycle of increasing pulmonary obstruction and inflammation that leads, without treatment, and in some cases, in spite of treatment, to bronchiectasis and end-stage lung disease [4].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, Buchwald M, Tsui LC. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989;245:1073–80.

    Article  PubMed  CAS  Google Scholar 

  2. Anderson MP, Gregory RJ, Thompson S, Souza DW, Paul S, Mulligan RC, Smith AE, Welsh MJ. Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science. 1991;253:202–5.

    Article  PubMed  CAS  Google Scholar 

  3. Cutting GR, Accurso F, Ramsey BW, and Welsh MJ. Cystic fibrosis. In: Valle D, Beaudet A, Vogelstein B, Kinzler K, Antonarakis S, Ballabio, editors. The online metabolic and molecular basis of inherited disease. http://www.ommbid.com/

  4. Boucher RC. Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu Rev Med. 2007;58:157–70.

    Article  PubMed  CAS  Google Scholar 

  5. di Sant’ Agnese PA, Darling RC, Perera GA, Shea E. Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas. Pediatrics. 1953;12:549.

    Google Scholar 

  6. Cystic Fibrosis Genetic Analysis Consortium. Worldwide survey of the deltaF508 mutation – report from the cystic fibrosis genetic analysis consortium (CFGAC). Am J Hum Genet. 1990;47:354–9.

    Google Scholar 

  7. Kerem E, Corey M, Kerem BS, Rommens J, Markiewicz D, Levison H, Tsui LC, Durie P. The relation between genotype and phenotype in cystic fibrosis–analysis of the most common mutation (delta F508). N Engl J Med. 1990;323:1517–22.

    Article  PubMed  CAS  Google Scholar 

  8. McKone EF, Emerson SS, Edwards KL, Aitken ML. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet. 2003;361:1671–6.

    Article  PubMed  CAS  Google Scholar 

  9. Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, Durie PR, Legrys VA, Massie J, Parad RB, Rock MJ, Campbell III PW, Cystic Fibrosis Foundation. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: cystic fibrosis foundation consensus report. J Pediatr. 2008;153:S4–14.

    Article  PubMed  Google Scholar 

  10. Anguiano A, Oates RD, Amos JA, Dean M, Gerrard B, Stewart C, Maher TA, White MB, Milunsky A. Congenital bilateral absence of the vas deferens. A primarily genital form of cystic fibrosis. JAMA. 1992;267(13):1794–7.

    Article  PubMed  CAS  Google Scholar 

  11. Cohn JA, Friedman KJ, Noone PG, Knowles MR, Silverman LM, Jowell PS. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N Engl J Med. 1998;339:653–8.

    Article  PubMed  CAS  Google Scholar 

  12. Bombieri C, Claustres M, De Boeck K, Derichs N, Dodge J, Girodon E, Sermet I, Schwarz M, Tzetis M, Wilschanski M, Bareil C, Bilton D, Castellani C, Cuppens H, Cutting GR, Drevínek P, Farrell P, Elborn JS, Jarvi K, Kerem B, Kerem E, Knowles M, Macek Jr M, Munck A, Radojkovic D, Seia M, Sheppard DN, Southern KW, Stuhrmann M, Tullis E, Zielenski J, Pignatti PF, Ferec C. Recommendations for the classification of diseases as CFTR-related disorders. J Cyst Fibros. 2011;10 Suppl 2:S86–102.

    Article  PubMed  CAS  Google Scholar 

  13. Anderson D. Cystic fibrosis of the pancreas and its relationship to celiac disease Clinical and pathologic study. Am J Dis Child. 1938;56:344.

    Google Scholar 

  14. Cystic Fibrosis Foundation. Annual report, p. 8. http://www.CFF.org (2010). Accessed 11 Feb 2012.

    Google Scholar 

  15. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, Turnbull A, Singh A, Joubran J, Hazlewood A, Zhou J, McCartney J, Arumugam V, Decker C, Yang J, Young C, Olson ER, Wine JJ, Frizzell RA, Ashlock M, Negulescu P. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA. 2009;106:18825–30.

    Article  PubMed  Google Scholar 

  16. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordoñez C, Elborn JS. VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365:1663–72.

    Article  PubMed  CAS  Google Scholar 

  17. Estivill X, McLean C, Nunes V, Casals T, Gallano P, Scambler P, Williamson R. Isolation of a new DNA marker in linkage disequilibrium with cystic fibrosis, situated between J3.11 (D7S8) and IRP. Am J Hum Genet. 1989;44:704–10.

    PubMed  CAS  Google Scholar 

  18. No Authors Listed. Statement from the National Institutes of Health workshop on population screening for the cystic fibrosis gene. N Engl J Med. 1990;323(1):70–1.

    Google Scholar 

  19. American College of Obstetricians and Gynecologists. Committee on Obstetrics: Maternal and Fetal Medicine. Current status of cystic fibrosis carrier screening. ACOG Committee Opinion No. 101. ACOG Comm Opin. 1991;101:1–2.

    Google Scholar 

  20. No Authors Listed. Statement of the American Society of Human Genetics on cystic fibrosis carrier screening. Am J Hum Genet. 1992;51(6):1443–4.

    Google Scholar 

  21. Grody WW. Cystic fibrosis: molecular diagnosis, population screening, and public policy. Arch Pathol Lab Med. 1999;123(11):1041–6.

    PubMed  CAS  Google Scholar 

  22. Zielenski J, Tsui LC. Cystic fibrosis: genotypic and phenotypic variations. Annu Rev Genet. 1995;29:777–807.

    Article  PubMed  CAS  Google Scholar 

  23. No Authors Listed. Genetic testing for cystic fibrosis. National Institutes of Health Consensus Development Conference Statement on genetic testing for cystic fibrosis. Arch Intern Med. 1999;159:1529–39.

    Google Scholar 

  24. Doksum T, Bernhardt BA, Holtzman NA. Carrier screening for cystic fibrosis among Maryland obstetricians before and after the 1997 NIH Consensus Conference. Genet Test. 2001;5:111–6.

    Article  PubMed  CAS  Google Scholar 

  25. Grody WW, Cutting GR, Klinger KW, Richards CS, Watson MS, Desnick RJ, Subcommittee on Cystic Fibrosis Screening, Accreditation of Genetic Services Committee, ACMG. Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet Med. 2001;3:149–54.

    Article  PubMed  CAS  Google Scholar 

  26. Watson MS, Cutting GR, Desnick RJ, Driscoll DA, Klinger K, Mennuti M, Palomaki GE, Popovich BW, Pratt VM, Rohlfs EM, Strom CM, Richards CS, Witt DR, Grody WW. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genet Med. 2001;3(2):149–54.

    Article  PubMed  Google Scholar 

  27. Rohlfs EM, Zhou Z, Sugarman EA, Heim RA, Pace RG, Knowles MR, Silverman LM, Allitto BA. The I148T CFTR allele occurs on multiple haplotypes: a complex allele is associated with cystic fibrosis. Genet Med. 2002;4:319–23.

    Article  PubMed  CAS  Google Scholar 

  28. Estivill X, Bancells C, Ramos C. Geographic distribution and regional origin of 272 cystic fibrosis mutations in European populations. The Biomed CF Mutation Analysis Consortium. Hum Mutat. 1997;10:135–54.

    Article  PubMed  CAS  Google Scholar 

  29. Heim RA, Sugarman EA, Allitto BA. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded, pan-ethnic mutation panel. Genet Med. 2001;3:168–76.

    Article  PubMed  CAS  Google Scholar 

  30. Wilfond BS, Nolan K. National policy development for the clinical application of genetic diagnostic technologies. Lessons from cystic fibrosis. JAMA. 1993;270:2948–54.

    Article  PubMed  CAS  Google Scholar 

  31. Chamberlain JS, Gibbs RA, Ranier JE, Nguyen PN, Caskey CT. Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplification. Nucleic Acids Res. 1988;16(23):11141–56.

    Article  PubMed  CAS  Google Scholar 

  32. Grody WW, Cutting GR, Watson MS. The cystic fibrosis mutation “arms race”: when less is more. Genet Med. 2007;9:739–44.

    Article  PubMed  Google Scholar 

  33. Sugarman EA, Rohlfs EM, Silverman LM, Allitto BA. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. Genet Med. 2004;6:392–9.

    Article  PubMed  Google Scholar 

  34. Highsmith WE, Friedman KJ, Burch LH, Spock A, Silverman LM, Boucher RC, Knowles MR. A CFTR mutation (D1152H) in a family with mild lung disease and normal sweat chlorides. Clin Genet. 2005;68:88–90.

    Article  PubMed  Google Scholar 

  35. Rozen R, Ferreira-Rajabi L, Robb L, Colman N. L206W mutation of the cystic fibrosis gene, relatively frequent in French Canadians, is associated with atypical presentations of cystic fibrosis. Am J Med Genet. 1995;57:437–9.

    Article  PubMed  CAS  Google Scholar 

  36. Rohlfs EM, Zhou Z, Heim RA, Nagan N, Rosenblum LS, Flynn K, Scholl T, Akmaev VR, Sirko-Osadsa DA, Allitto BA, Sugarman EA. Cystic fibrosis carrier testing in an ethnically diverse US population. Clin Chem. 2011;57:841–8.

    Article  PubMed  CAS  Google Scholar 

  37. Strom CM, Crossley B, Buller-Buerkle A, Jarvis M, Quan F, Peng M, Muralidharan K, Pratt V, Redman JB, Sun W. Cystic fibrosis testing 8 years on: lessons learned from carrier screening and sequencing analysis. Genet Med. 2011;13:166–72.

    Article  PubMed  Google Scholar 

  38. The Quality Control Materials for Genetic Testing Group. Developing a sustainable process to provide quality control materials for genetic testing. Genet Med. 2005;7(8):534–49.

    Article  Google Scholar 

  39. Pratt VM, Caggana M, Bridges C, Buller AM, DiAntonio L, Highsmith WE, Holtegaard LM, Muralidharan K, Rohlfs EM, Tarleton J, Toji L, Barker SD, Kalman LV. Development of genomic reference materials for cystic fibrosis genetic testing. J Mol Diagn. 2009;11:186–93.

    Article  PubMed  CAS  Google Scholar 

  40. Dupuis A, Hamilton D, Cole DE, Corey M. Cystic fibrosis birth rates in Canada: a decreasing trend since the onset of genetic testing. J Pediatr. 2005;147(3):312–5.

    Article  PubMed  Google Scholar 

  41. Hale JE, Parad RB, Comeau AM. Newborn screening showing decreasing incidence of cystic fibrosis. N Engl J Med. 2008;358:973–4.

    Article  PubMed  CAS  Google Scholar 

  42. Castellani C, Picci L, Tamanini A, Girardi P, Rizzotti P, Assael BM. Association between carrier screening and incidence of cystic fibrosis. JAMA. 2009;302:2573–9.

    Article  PubMed  CAS  Google Scholar 

  43. Guthrie R. The introduction of newborn screening for phenylketonuria. A personal history. Eur J Pediatr. 1996;155 Suppl 1:S4–5.

    Article  PubMed  Google Scholar 

  44. Crossley JR, Elliott RB, Smith PA. Dried-blood spot screening for cystic fibrosis in the newborn. Lancet. 1979;1:472–4.

    Article  PubMed  CAS  Google Scholar 

  45. Watson MS, Lloyd-Puryear MA, Mann MY, Rinaldo P, Howell RR. Newborn screening: toward a uniform screening panel and system [main report]. Genet Med. 2006;8:12S–252S.

    Article  Google Scholar 

  46. Massie RJ, Curnow L, Glazner J, Armstrong DS, Francis I. Lessons learned from 20 years of newborn screening for cystic fibrosis. Med J Aust. 2012;196(1):67–70.

    Article  PubMed  Google Scholar 

  47. Balfour-Lynn IM. Newborn screening for cystic fibrosis: evidence for benefit. Arch Dis Child. 2008;93(1):7–10.

    Article  PubMed  Google Scholar 

  48. Farrell PM, Lai HJ, Li Z, Kosorok MR, Laxova A, Green CG, Collins J, Hoffman G, Laessig R, Rock MJ, Splaingard ML. Evidence on improved outcomes with early diagnosis of cystic fibrosis through neonatal screening: enough is enough! J Pediatr. 2005;147(3 Suppl):S30–6.

    PubMed  Google Scholar 

  49. Chatfield S, Owen G, Ryley HC, Williams J, Alfaham M, Goodchild MC, Weller P. Neonatal screening for cystic fibrosis in Wales and the West Midlands: clinical assessment after five years of screening. Arch Dis Child. 1991;66:29–33.

    Article  PubMed  CAS  Google Scholar 

  50. CLSI. Newborn screening for cystic fibrosis: approved guideline. CLSI Document I/LA35-A. Wayne, PA. Clinical and Laboratory Standards Institute.

    Google Scholar 

  51. Castellani C. Evidence for newborn screening for cystic fibrosis. Paediatr Respir Rev. 2003;4:278–84.

    Article  PubMed  Google Scholar 

  52. Southern KW, Mérelle MM, Dankert-Roelse JE, Nagelkerke AD. Newborn screening for cystic fibrosis. Cochrane Database Syst Rev. 2009;1, CD001402.

    PubMed  Google Scholar 

  53. Salvatore D, Buzzetti R, Baldo E, Forneris MP, Lucidi V, Manunza D, Marinelli I, Messore B, Neri AS, Raia V, Furnari ML, Mastella G. An overview of international literature from cystic fibrosis registries 2. Neonatal screening and nutrition/growth. J Cyst Fibros. 2010;9(2):75–83.

    Article  PubMed  Google Scholar 

  54. Castellani C, Southern KW, Brownlee K, Dankert Roelse J, Duff A, Farrell M, Mehta A, Munck A, Pollitt R, Sermet-Gaudelus I, Wilcken B, Ballmann M, Corbetta C, de Monestrol I, Farrell P, Feilcke M, Férec C, Gartner S, Gaskin K, Hammermann J, Kashirskaya N, Loeber G, Macek Jr M, Mehta G, Reiman A, Rizzotti P, Sammon A, Sands D, Smyth A, Sommerburg O, Torresani T, Travert G, Vernooij A, Elborn S. European best practice guidelines for cystic fibrosis neonatal screening. J Cyst Fibros. 2009;8(3):153–73.

    Article  PubMed  Google Scholar 

  55. Collins JL, La Pean A, O’Tool F, Eskra KL, Roedl SJ, Tluczek A, Farrell MH. Factors that influence parents’ experiences with results disclosure after newborn screening identifies genetic carrier status for cystic fibrosis or sickle cell hemoglobinopathy. Patient Educ Couns. 2013;90:378–85.

    Article  PubMed  Google Scholar 

  56. Farrell PM, Shen G, Splaingard M, Colby CE, Laxova A, Kosorok MR, Rock MJ, Mischler EH. Acquisition of Pseudomonas aeruginosa in children with cystic fibrosis. Pediatrics. 1997;100:E2.

    Article  PubMed  CAS  Google Scholar 

  57. Kosorok MR, Jalaluddin M, Farrell PM, Shen G, Colby CE, Laxova A, Rock MJ, Splaingard M. Comprehensive analysis of risk factors for acquisition of Pseudomonas aeruginosa in young children with cystic fibrosis. Pediatr Pulmonol. 1998;26:81–8.

    Article  PubMed  CAS  Google Scholar 

  58. Hayes Jr D, West SE, Rock MJ, Li Z, Splaingard ML, Farrell PM. Pseudomonas aeruginosa in children with cystic fibrosis diagnosed through newborn screening: assessment of clinic exposures and microbial genotypes. Pediatr Pulmonol. 2010;45:708–16.

    Article  PubMed  Google Scholar 

  59. Grosse SD, Boyle CA, Botkin JR, Comeau AM, Kharrazi M, Rosenfeld M, Wilfond BS, CDC. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep. 2004;53:1–36.

    Google Scholar 

  60. Sontag MK, Hammond KB, Zielenski J, Wagener JS, Accurso FJ. Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes. J Pediatr. 2005;147(3 Suppl):S83–8.

    PubMed  CAS  Google Scholar 

  61. Gregg RG, Wilfond BS, Farrell PM, Laxova A, Hassemer D, Mischler EH. Application of DNA analysis in a population-screening program for neonatal diagnosis of cystic fibrosis (CF): comparison of screening protocols. Am J Hum Genet. 1993;52:616–26.

    PubMed  CAS  Google Scholar 

  62. Larsen J, Campbell S, Faragher EB, Götz M, Eichler I, Waldherr S, Dobianer K, Spona J. Cystic fibrosis screening in neonates–measurement of immunoreactive trypsin and direct genotype analysis for delta F508 mutation. Eur J Pediatr. 1994;153:569–73.

    Article  PubMed  CAS  Google Scholar 

  63. Baker MW, Groose M, Hoffman G, Rock M, Levy H, Farrell PM. Optimal DNA tier for the IRT/DNA algorithm determined by CFTR mutation results over 14 years of newborn screening. J Cyst Fibros. 2011;10:278–81.

    Article  PubMed  CAS  Google Scholar 

  64. Sontag MK, Wright D, Beebe J, Accurso FJ, Sagel SD. A new cystic fibrosis newborn screening algorithm: IRT/IRT1 upward arrow/DNA. J Pediatr. 2009;155(5):618–22.

    Article  PubMed  CAS  Google Scholar 

  65. Keiles S, Koepke R, Parad R, Kharrazi M, California Cystic Fibrosis Newborn Screening Consortium. Impact of IVS8-(TG)m(T)n on IRT and sweat chloride levels in newborns identified by California CF newborn screening. J Cyst Fibros. 2012;11:257–60.

    Article  PubMed  CAS  Google Scholar 

  66. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002;30(12):e57.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Molecular Genetics Laboratory, Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN, USA

    W. Edward Highsmith Jr. Ph.D.

Authors
  1. W. Edward Highsmith Jr. Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W. Edward Highsmith Jr. Ph.D. .

Editor information

Editors and Affiliations

  1. Medicine and Pathology Molecular Genetics Laboratory, Mayo Clinic College of Medicine Department of Laboratory, Rochester, Minnesota, USA

    W. Edward Highsmith, Jr.

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Highsmith, W.E. (2014). Cystic Fibrosis: Carrier Testing, Newborn Screening, and Diagnostic Testing. In: Highsmith, Jr., W. (eds) Molecular Diagnostics. Molecular and Translational Medicine. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4614-8127-0_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-8127-0_11

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4614-8126-3

  • Online ISBN: 978-1-4614-8127-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation